The Koch Institute and BioMicro Center at MIT are the first partners in the Boston area to automate ChIP and methylation assays using Diagenode's SX-8G IP-Star® automation system. The system allows for increased efficiency and consistency in epigenetic assays. MIT scientists validated the system and used it to screen antibodies for ChIP-Seq experiments. The customizable automation will support growing research interests in epigenetics at MIT. This marks the first partnership between Diagenode and MIT researchers.
Accelerating COVID-19 Therapies: How a streamlined biosafety strategy can get...Merck Life Sciences
Access the interactive recording: https://bit.ly/2xB2eRs
Abstract:
Vaccine and other biologic developers have long relied on traditional, growth-based methods for the detection of adventitious agents in a biosafety testing package. However, at a time where speed is of the essence, relying on testing methods that take many weeks is a real concern. Fortunately, alternative rapid detection methods can shorten timelines significantly — especially for Phase I testing. Here we will take you through these rapid alternatives and outline a testing strategy that can bring your therapy to the clinic faster.
Biopharma Production and Development China 2015 Rita Barry
As the BioPharma industry grows in China and the Asian region, we invite you to be a part of this tremendous growth & development opportunities!
IBC’s Biopharma Development & Production Week in China is THE meeting place for biopharma industry professionals and scientists to get the highest quality and practical information that will enable them to develop competitive advantages and advance their capabilities in developing and manufacturing cell lines, biosimilars, biobetters, vaccines or novel biologics.
Top Reasons Why You Should Participate:
- Establish Business Partnerships with Chinese/Asian drug developers and contract
manufacturers
- Learn technical & practical know how from experiences on the ground in Asia
- Showcase your cutting edge solutions in front of key China/Asian Biopharma
decision makers
http://www.biopharmaproduction.com
Nanotechnology is the science of understanding, inventing, and controlling objects which are built in the scales of nanometers (one nanometer is one-billionth of a meter). Using Nanotechnology, manufacturers can compose components such as batteries, robots, or tools at a very small scale which may be later added to medical devices. With advanced scientific developments over a decade, Nanotechnology is proving itself to be useful in the healthcare domain including alternative drug production, cosmetic products, and medical devices. As, in such cases, human safety is the highest priority, these devices or applications which utilize Nanotechnology should be FDA compliant before they are marketed for use...
Accelerating COVID-19 Therapies: How a streamlined biosafety strategy can get...Merck Life Sciences
Access the interactive recording: https://bit.ly/2xB2eRs
Abstract:
Vaccine and other biologic developers have long relied on traditional, growth-based methods for the detection of adventitious agents in a biosafety testing package. However, at a time where speed is of the essence, relying on testing methods that take many weeks is a real concern. Fortunately, alternative rapid detection methods can shorten timelines significantly — especially for Phase I testing. Here we will take you through these rapid alternatives and outline a testing strategy that can bring your therapy to the clinic faster.
Biopharma Production and Development China 2015 Rita Barry
As the BioPharma industry grows in China and the Asian region, we invite you to be a part of this tremendous growth & development opportunities!
IBC’s Biopharma Development & Production Week in China is THE meeting place for biopharma industry professionals and scientists to get the highest quality and practical information that will enable them to develop competitive advantages and advance their capabilities in developing and manufacturing cell lines, biosimilars, biobetters, vaccines or novel biologics.
Top Reasons Why You Should Participate:
- Establish Business Partnerships with Chinese/Asian drug developers and contract
manufacturers
- Learn technical & practical know how from experiences on the ground in Asia
- Showcase your cutting edge solutions in front of key China/Asian Biopharma
decision makers
http://www.biopharmaproduction.com
Nanotechnology is the science of understanding, inventing, and controlling objects which are built in the scales of nanometers (one nanometer is one-billionth of a meter). Using Nanotechnology, manufacturers can compose components such as batteries, robots, or tools at a very small scale which may be later added to medical devices. With advanced scientific developments over a decade, Nanotechnology is proving itself to be useful in the healthcare domain including alternative drug production, cosmetic products, and medical devices. As, in such cases, human safety is the highest priority, these devices or applications which utilize Nanotechnology should be FDA compliant before they are marketed for use...
This research will investigate technologies to enable the development of spore traps capable of in-field detection, and identification, of specific biosecurity threats.
East Coast Fever Vaccine Frontier Research ProjectILRI
Presentation by John McDermott to the CGIAR Alliance Deputy Executive (ADE) and Private Sector Committee (PSC) Workshop on Public Private Partnerships , November 11-13, 2009, Zurich, Switzerland.
http://www.cgiar.org/psc/
New PDA/IPEC Technical Report on Excipient Risk Assessment - insights for dru...MilliporeSigma
Access the interactive recording: https://bit.ly/37HqbTK
Abstract:
Since March 2016 the EU Guideline to ascertain the appropriate GMP for pharmaceutical excipients is legally binding. Although the EU Guideline itself provides a high level description how to perform the risk assessment, the implementation can be challenging. In January 2018 PDA and IPEC formed a joint Task Force with the objective to develop a joint Technical Report to share best practices with industry. This Technical Report was published in December 2019. In this webinar you will be introduced to the new Technical Report, its objective, proposed approaches and examples shared by PDA/IPEC member companies.
Roundup of This Year's AACC Meeting in AtlantaBruce Carlson
The American Association of Clinical Chemistry was held this year in Atlanta, GA. Kalorama was at the meeting and notes several developments, with a particular focus on point-of-care.
This research will investigate technologies to enable the development of spore traps capable of in-field detection, and identification, of specific biosecurity threats.
East Coast Fever Vaccine Frontier Research ProjectILRI
Presentation by John McDermott to the CGIAR Alliance Deputy Executive (ADE) and Private Sector Committee (PSC) Workshop on Public Private Partnerships , November 11-13, 2009, Zurich, Switzerland.
http://www.cgiar.org/psc/
New PDA/IPEC Technical Report on Excipient Risk Assessment - insights for dru...MilliporeSigma
Access the interactive recording: https://bit.ly/37HqbTK
Abstract:
Since March 2016 the EU Guideline to ascertain the appropriate GMP for pharmaceutical excipients is legally binding. Although the EU Guideline itself provides a high level description how to perform the risk assessment, the implementation can be challenging. In January 2018 PDA and IPEC formed a joint Task Force with the objective to develop a joint Technical Report to share best practices with industry. This Technical Report was published in December 2019. In this webinar you will be introduced to the new Technical Report, its objective, proposed approaches and examples shared by PDA/IPEC member companies.
Roundup of This Year's AACC Meeting in AtlantaBruce Carlson
The American Association of Clinical Chemistry was held this year in Atlanta, GA. Kalorama was at the meeting and notes several developments, with a particular focus on point-of-care.
Miniature Drug delivery System uses micro-fabricated devices to administer drugs to the host and has advantages over a conventional drug delivery system
A MEMS based Implantable Drug Delivery System (IDDS) is discussed. The heart of the system is an in-plane MEMS micropumps enables us to make a compact, inexpensive system. A conceptual IDDS design is proposed. This design consists of an implantable unit which houses the micropumps, electronic and power circuitry. This implantable unit is connected to a subcutaneous port via a silicone catheter. The subcutaneous port acts as a refillable reservoir. This leads to a reduction in unit volume and makes the system customizable. The IDDS pumps drug into surrounding tissue with the help of a MEMS based micropumps. Similarly Microneedles are also used in drug administration.
This report gives an overview of patenting activity around Miniature Drug Delivery System. Smart drug delivery system is used for delivering drugs to the host effectively and improves the quality of life of the patients. Patents were categorized as per key Drug Delivery administration methods, types of sensors, applications, communication techniques and analyzed for generating different trends with Patent iNSIGHT Pro.
Miniature Drug Delivery System technology has seen a consistent increase in the number of patent publications from 2008 till 2012 as the need for smart drug delivery has increase globally.
Published: Apr 30, 2013
Next Generation Sequencing & DNA Synthesis: Technology, Consumables Manufactu...Yole Developpement
With the sequencer installed base doubling, the sequencing consumables market will reach $7.8B by 2024.
More information on that report at https://www.i-micronews.com/products/next-generation-sequencing-dna-synthesis-technology-consumables-manufacturing-and-market-trends-2019/
Status of the Microfluidics Industry 2019 report by Yole Développement Yole Developpement
Diversification of microfluidic technologies has led to burgeoning new applications and market growth, driving players’ interest and M&A.
More information on https://www.i-micronews.com/products/status-of-the-microfluidics-industry-2019/
Organs-On-Chips Market and Technology Landscape 2019 report by Yole Développe...Yole Developpement
Market growth is pushing changes in materials and technologies.
More information on https://www.i-micronews.com/products/organs-on-chips-market-and-technology-landscape-2019/
Cameras for Microscopy and Next-Generation Sequencing 2019 report by Yole Dév...Yole Developpement
Disposable image sensors: a revolution for microscopy and next-generation sequencing.
More information on: https://www.i-micronews.com/products/cameras-for-microscopy-and-next-generation-sequencing-2019/
1. Europe - Diagenode sa. / orders@diagenode.com / info@diagenode.com // North America - Diagenode Inc. / orders.na@diagenode.com / info.na@diagenode.com
www.diagenode.com 1
DENVILLE, NJ and LIEGE, BELGIUM--(Marketwire - Aug 16, 2011) - The Koch Institute and the BioMicro Center at MIT are
the first partners in the Boston area to be able to fully automate ChIP and Methylation assays using Diagenode’s SX-8G IP-
Star®
automation system. The SX-8G IP-Star®
system revolutionizes the workflow and the hands on time requirements of
many common epigenetic assays from ChIP to Methylation. The platform will allow MIT researchers to increase efficiency
and consistency of many epigenetic assays. Scientists at the MIT BioMicro Center conducted extensive tests of the SX-8G
IP-Star®
under normal lab working conditions. In addition to validating the SX-8G IP-Star®
, MIT scientists used the system
as a quality control for screening new antibodies for ChIP-Seq experiments.
Robert G. Urban, Ph.D., Executive Director of the Koch Institute at MIT, explains, “The addition of customizable epigenetic
assay automation to support the growing experimental needs of our oncology research community represents an important
new approach for us. The automation capability of the SX-8G IP-Star®
system has greatly simplified the quality control of
ChIP upfront of our ChIP-Seq experiments. Diagenode’s SX-8G IP-Star®
offers us a highly flexible and open platform that will
support the growing research interest in epigenetics across MIT.”
This system marks the first partnership between Diagenode and MIT researchers. Ignacio Mazon, Ph.D., SX-8G IP-Star®
Field Application Scientist, noted, “We are honored to have some of the best cancer researchers in the world working on our
platform. Diagenode believes the BioMicro Center’s expertise in ChIP-Seq will be able to take full advantage of the benefits
of the SX-8G IP-Star®
.”
About Diagenode
Diagenode is a multinational life science company that develops and commercializes innovative instruments and reagents
for epigenetic research. Major product lines include SX-8G IP-Star®
Automation, Bioruptor®
Sonication, epigenetic targeted
antibodies and kits. Founded in 2004 in Liège (Belgium), Diagenode has offices in Liège, Belgium and Denville, New Jersey.
The David H. Koch Institute for Integrative Cancer
Research and the BioMicro Center at Massachusetts
Institute of Technology Partner With Diagenode for
Automating Epigenetic Assays
PRESS RELEASE
www.diagenode.com
Jason Holzman
US Sales and Marketing Manager
Diagenode Inc.
info.na@diagenode.com
Contact Information PR-D.H.Koch.IPS_17_08_11
